Literature DB >> 16112180

Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test?

Jaume Ordi1, Imma Alonso, Aureli Torné, Roser Esteve, Erika Sierra, Elias Campo, Luis M Puig-Tintoré.   

Abstract

OBJECTIVE: The aim of the study was to evaluate whether the results of the Hybrid Capture II (HCII) assay for detecting high-grade squamous intraepithelial lesions (H-SIL) or cervical carcinoma can be improved by increasing the relative light units (RLU) level. STUDY
DESIGN: We included 2271 women (mean age 38.7 +/- 12.3, range 15-92) referred to a colposcopic clinic due to cytology of atypical cells of unknown significance, SIL or carcinoma. All women underwent a new Pap test, HR-HPV detection using HCII and colposcopy with biopsy of suspicious areas when present.
RESULTS: HR-HPV was detected in 91.7% of carcinomas, 96.6% of H-SIL, 85.1% of low-grade SIL and 21.6% of cases with no lesion. The probability of harboring an H-SIL or a carcinoma significantly increased as RLU increased (P = 0.01). The sensitivity and specificity for H-SIL or carcinoma at different cutoffs were 95.7 and 54.6 at 1 RLU, 93.9 and 59.6 at 2 RLU, 90.1 and 65.1 at 5 RLU and 85.7 and 68.7 at 10 RLU. The percentage of cases not detected with HCII increased from 2.4% for cases with <1 RLU to 9.5% for cases between 1 and 2 RLU, 14.8% between 2 and 3 RLU, 21.7% between 3 and 5 RLU and 28.4% between 5 and 10 RLU.
CONCLUSION: The use of a higher cutoff (higher viral load) in the HCII should not be recommended because it significantly increases the number of cases with H-SIL or carcinoma not detected, reducing the sensitivity and negative predictive value of the test.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112180     DOI: 10.1016/j.ygyno.2005.07.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology.

Authors:  M Origoni; G Carminati; S Rolla; M Clementi; M Sideri; M T Sandri; M Candiani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-01       Impact factor: 3.267

3.  mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer.

Authors:  Marta Del Pino; Cecilia Svanholm-Barrie; Aureli Torné; Lorena Marimon; Jina Gaber; Amaia Sagasta; David H Persing; Jaume Ordi
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

4.  Hybrid capture 2 test results after an initial equivocal RLU/CO value are dependent on age.

Authors:  Camille T Elkins; Christiaan E de Vries; Julie Stephens; Adrian A Suarez
Journal:  Am J Clin Pathol       Date:  2013-05       Impact factor: 2.493

5.  p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix.

Authors:  Amaia Sagasta; Paola Castillo; Adela Saco; Aureli Torné; Roser Esteve; Lorena Marimon; Jaume Ordi; Marta Del Pino
Journal:  Mod Pathol       Date:  2015-11-06       Impact factor: 7.842

6.  Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study.

Authors:  Li Ma; Mei-Lu Bian; Jiao-Ying Cheng; Wei Xiao; Min Hao; Juan Zhu; Ying Chen; Jun Liu
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

7.  Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women.

Authors:  Eun Young Ki; Yoon Kyung Lee; Ahwon Lee; Jong Sup Park
Journal:  Yonsei Med J       Date:  2018-07       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.